drugset

drugset / Trial / NCT06497127

A Study in Patients With Mixed Dyslipidemia

NCT06497127 ↗

Phase 2 Active not recruiting 145 enrolled Shanghai Argo Biopharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 2 in Patients With Mixed Dyslipidemia

Timeline

Start: 2024-02-28
Primary completion: 2026-06-30
Completion: 2028-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BW-00112	Unknown	150 mg	Subcutaneous
Subject	BW-00112	Unknown	300 mg	Subcutaneous
Subject	BW-00112	Unknown	600 mg	Subcutaneous

Indications